PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30594176-12 2018 CONCLUSIONS: MLH1 may render endometrial carcinoma cells more sensitive to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway. Cisplatin 75-84 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 108-113 23598363-3 2013 Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin. Cisplatin 133-142 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 14-19 26126715-10 2015 In mice engineered to express a nuclear import-defective mutant of ABL, miR-34c, but not miR-34a, expression was reduced in the kidney, and apoptosis of the renal epithelial cells was impaired in response to cisplatin. Cisplatin 208-217 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 67-70 23598363-11 2013 The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression. Cisplatin 63-72 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 34-39 23598363-11 2013 The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression. Cisplatin 63-72 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 113-118 23598363-11 2013 The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression. Cisplatin 63-72 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 113-118 23598363-6 2013 We found that, before apoptosis, cisplatin induces c-Abl and TAp73 expression in the oocyte. Cisplatin 33-42 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 51-56 23598363-12 2013 Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis. Cisplatin 58-67 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 101-106 23598363-13 2013 Thus, imatinib and other c-Abl kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy. Cisplatin 87-96 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 25-30 23598363-8 2013 While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death. Cisplatin 141-150 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 183-188 23660976-0 2013 Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity. Cisplatin 85-94 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 22-25 23660976-3 2013 We show here that cisplatin-induced apoptosis is defective in the renal proximal tubule cells (RPTC) from the Abl(mu/mu) mice. Cisplatin 18-27 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 110-119 23660976-4 2013 When injected with cisplatin, we found similar levels of platinum in the Abl(+/+) and the Abl(mu/mu) kidneys, as well as similar initial inductions of p53 and PUMAalpha expression. Cisplatin 19-28 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 73-76 23660976-4 2013 When injected with cisplatin, we found similar levels of platinum in the Abl(+/+) and the Abl(mu/mu) kidneys, as well as similar initial inductions of p53 and PUMAalpha expression. Cisplatin 19-28 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 90-99 23660976-6 2013 Co-treatment of cisplatin with the Abl kinase inhibitor, imatinib, reduced the accumulation of p53 and PUMAalpha in the Abl(+/+) but not in the Abl(mu/mu) kidneys. Cisplatin 16-25 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 35-38 23660976-6 2013 Co-treatment of cisplatin with the Abl kinase inhibitor, imatinib, reduced the accumulation of p53 and PUMAalpha in the Abl(+/+) but not in the Abl(mu/mu) kidneys. Cisplatin 16-25 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 120-123 23660976-6 2013 Co-treatment of cisplatin with the Abl kinase inhibitor, imatinib, reduced the accumulation of p53 and PUMAalpha in the Abl(+/+) but not in the Abl(mu/mu) kidneys. Cisplatin 16-25 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 144-153 23660976-9 2013 These results provide in vivo evidence for the pro-apoptotic function of Abl, and show that its nuclear localization and tyrosine kinase activity are both required for the sustained expression of p53 and PUMAalpha in cisplatin-induced renal apoptosis. Cisplatin 217-226 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 73-76 10391249-0 1999 The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Cisplatin 65-74 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 20-25 19783996-3 2009 In cell lines, upon cisplatin treatment, c-Abl phosphorylates TAp63 on specific tyrosine residues. Cisplatin 20-29 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 41-46 19783996-6 2009 Treatment with the c-Abl kinase inhibitor imatinib counteracts these cisplatin-induced effects. Cisplatin 69-78 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 19-24 15302867-2 2004 However, cisplatin, a DNA damage-inducing chemotherapeutic agent, is thought to regulate p73 only by affecting its stability through mechanisms involving the MLH-1/c-Abl signaling cascade. Cisplatin 9-18 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 164-169 11390389-10 2001 Cell treatment with the DNA-damaging agent cisplatin activated c-Abl kinase and increased Tyr phosphorylation of PLSCR1. Cisplatin 43-52 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 63-68 20818431-7 2010 Recent findings have implicated Abl in a cisplatin-induced signaling pathway eliciting death of immature oocytes. Cisplatin 41-50 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 32-35 20818431-9 2010 Of note, pharmacological inhibition of Abl protects the ovarian reserve from the toxic effects of cisplatin. Cisplatin 98-107 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 39-42 15547703-0 2004 Induction of p21 and nuclear accumulation of TAp73alpha and c-abl during apoptosis of cisplatin-treated primary pancreatic acinar cells. Cisplatin 86-95 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 60-65 10391249-7 1999 The half-life of p73 is prolonged by cisplatin and by co-expression with c-Abl tyrosine kinase; the apoptosis-inducing function of p73 is also enhanced by the c-Abl kinase. Cisplatin 37-46 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 159-164 10391249-8 1999 Mouse embryo fibroblasts deficient in mismatch repair or in c-Abl do not upregulate p73 and are more resistant to killing by cisplatin. Cisplatin 125-134 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 60-65 10391249-9 1999 Our results indicate that c-Abl and p73 are components of a mismatch-repair-dependent apoptosis pathway which contributes to cisplatin-induced cytotoxicity. Cisplatin 125-134 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 26-31 33458904-8 2021 RESULTS: Cisplatin-related PF apoptosis via the ABL/TAp63 pathway was targeted with a tyrosine kinase inhibitor, imatinib, in mice, but effects were recently challenged by findings on human ovarian xenografts in mice. Cisplatin 9-18 c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus 48-51